Literature DB >> 15808178

Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib.

Mercedes Hurtado-Sarrió1, Antonio Duch-Samper, Juan Taboada-Esteve, Jesús A Martínez-Dominguez, M Leonor Senent-Peris, Jose L Menezo-Rozalén.   

Abstract

PURPOSE: Anterior chamber involvement is unusual in patients with acute lymphoblastic leukemia (ALL) and has never been described in the setting of Ph+ (Philadelphia chromosome-positive) ALL. Moreover, there have been no reports of this complication as a primary relapse in a patient treated with imatinib.
DESIGN: Interventional case report.
METHODS: A 55-year-old woman with Ph+ ALL in complete remission with imatinib and presenting unilateral anterior uveitis at initial examination was clinically evaluated. Hematologic and ocular studies were performed: blood films, bone marrow smears, and anterior chamber paracentesis with aqueous fluid cytology.
RESULTS: Although there was no evidence of leukemia in the blood or bone marrow samples, aqueous fluid cytology identified Ph+ positive lymphoblastic leukemic cells.
CONCLUSIONS: The patient had developed anterior chamber infiltration without hematological relapse while treated with imatinib. In our opinion, paracentesis should be performed without delay when uveitis develops in ALL, regardless of systemic relapse.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15808178     DOI: 10.1016/j.ajo.2004.09.075

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  2 in total

1.  Acute Bilateral Hypopyon in Acute Lymphocytic Leukaemia.

Authors:  R Lakhtakia; A Sinha; S K Anand; A K Dhar; P K Thakur; A Mehta
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  Intraocular infiltration of Philadelphia chromosome-positive acute lymphoblastic leukemia diagnosed by polymerase chain reaction from the aqueous humor: A case report.

Authors:  Miki Hiraoka; Hiroshi Ohguro; Hiroshi Ikeda; Daisuke Furuya; Satoshi Takahashi
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.